Lexicon Pharmaceuticals (LXRX) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a hold rating to a sell rating in a report published on Thursday, April 18th, BidAskClub reports.

Other analysts have also issued research reports about the stock. Gabelli lowered shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, March 13th. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, January 18th. ValuEngine raised shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, March 12th. Wedbush boosted their price objective on shares of Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the company an outperform rating in a research note on Monday, March 4th. Finally, Stifel Nicolaus reduced their price objective on shares of Lexicon Pharmaceuticals from $14.00 to $10.00 and set a buy rating for the company in a research note on Monday, March 25th. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Lexicon Pharmaceuticals has a consensus rating of Hold and an average target price of $16.38.

Lexicon Pharmaceuticals stock traded down $0.11 during midday trading on Thursday, hitting $6.77. 350,540 shares of the stock were exchanged, compared to its average volume of 659,445. The stock has a market cap of $719.45 million, a PE ratio of -5.94 and a beta of 0.72. Lexicon Pharmaceuticals has a 52-week low of $4.25 and a 52-week high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $9.20 million for the quarter, compared to analyst estimates of $13.26 million. Lexicon Pharmaceuticals had a negative net margin of 214.93% and a negative return on equity of 911.37%. The company’s revenue for the quarter was down 63.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. On average, equities analysts predict that Lexicon Pharmaceuticals will post -0.47 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA grew its stake in Lexicon Pharmaceuticals by 940.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 8,979 shares in the last quarter. Pegasus Asset Management Inc. purchased a new position in Lexicon Pharmaceuticals in the 4th quarter worth approximately $66,000. Wealth & Pension Services Group Inc. purchased a new position in Lexicon Pharmaceuticals in the 1st quarter worth approximately $60,000. Paloma Partners Management Co purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $73,000. Finally, Federated Investors Inc. PA boosted its stake in shares of Lexicon Pharmaceuticals by 1,317.0% in the 1st quarter. Federated Investors Inc. PA now owns 12,611 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 11,721 shares in the last quarter.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Further Reading: Are all No-Load Funds Equal?

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.